Posted by Michael Wonder on 27 Jul 2018
Amgen's new migraine drug hits insurance hurdles
26 July 2018 - Amgen's push to get patients on its new US$575 a month migraine drug before competition emerges in September is facing barriers from insurers.
Bracing for a flood of costly prescription claims for the drug, Aimovig, large insurers such as Anthem Inc have set requirements for patients to document how they suffer from a defined number of headaches each month, and show that they have tried older migraine drugs first.
Others have made it even harder.
